Massachusetts General Hospital: Depressive Disorder, Treatment-Resistant trials

The registry lists 11 Depressive Disorder, Treatment-Resistant studies with Massachusetts General Hospital as lead sponsor. 2 are open to participants now and 7 have results posted.

Phase 2 4Phase 4 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effect of Neurofeedback and TMSNot yet recruitingNCT07892287Not applicable
• Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant DepressionRecruitingNCT07563868Not applicable
• A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)CompletedNCT03149991Phase 4Results posted
• Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid AllopregnanoloneCompletedNCT02900092Not applicableResults posted
• Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)CompletedNCT01920555Phase 2Results posted
• Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant DepressionTerminatedNCT01913535Phase 2Results posted
• Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant DepressionCompletedNCT01654796Not applicableResults posted
• Pharmacogenomics for Antidepressant Guidance and EducationTerminatedNCT01555021Results posted
• Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant DepressionCompletedNCT00093847Phase 2Results posted
• Specialized Pro-resolving Lipid Mediators and Treatment Resistant DepressionActive, not recruitingNCT05774665Phase 2
• Neurocognitive Features of Patients With Treatment-Resistant DepressionCompletedNCT03134066